S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
5 Trends You Need to Know This Quarter
MarketBeat Week in Review – 4/8 - 4/12
Faced with possibly paying for news, Google removes links to California news sites for some users
Argentina's populist president meets billionaire Elon Musk in Texas — and a bromance is born
Diplomat tapped as Latvia's new foreign minister as incumbent quits following flights scandal
It's almost April 15. Here's how to reduce stress and get your taxes done
Nearing 50 Supreme Court arguments in, lawyer Lisa Blatt keeps winning
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
5 Trends You Need to Know This Quarter
MarketBeat Week in Review – 4/8 - 4/12
Faced with possibly paying for news, Google removes links to California news sites for some users
Argentina's populist president meets billionaire Elon Musk in Texas — and a bromance is born
Diplomat tapped as Latvia's new foreign minister as incumbent quits following flights scandal
It's almost April 15. Here's how to reduce stress and get your taxes done
Nearing 50 Supreme Court arguments in, lawyer Lisa Blatt keeps winning
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
5 Trends You Need to Know This Quarter
MarketBeat Week in Review – 4/8 - 4/12
Faced with possibly paying for news, Google removes links to California news sites for some users
Argentina's populist president meets billionaire Elon Musk in Texas — and a bromance is born
Diplomat tapped as Latvia's new foreign minister as incumbent quits following flights scandal
It's almost April 15. Here's how to reduce stress and get your taxes done
Nearing 50 Supreme Court arguments in, lawyer Lisa Blatt keeps winning
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
5 Trends You Need to Know This Quarter
MarketBeat Week in Review – 4/8 - 4/12
Faced with possibly paying for news, Google removes links to California news sites for some users
Argentina's populist president meets billionaire Elon Musk in Texas — and a bromance is born
Diplomat tapped as Latvia's new foreign minister as incumbent quits following flights scandal
It's almost April 15. Here's how to reduce stress and get your taxes done
Nearing 50 Supreme Court arguments in, lawyer Lisa Blatt keeps winning
NYSEARCA:GERM

Amplify Treatments, Testing and Advancements ETF (GERM) Price, Holdings, & News

$17.08
-0.63 (-3.56%)
(As of 04/12/2024 ET)
Today's Range
$16.97
$17.08
50-Day Range
$16.97
$18.95
52-Week Range
$15.67
$22.00
Volume
738 shs
Average Volume
2,172 shs
Market Capitalization
$13.66 million
Assets Under Management
$10.69 million
Dividend Yield
0.82%
Net Expense Ratio
0.68%
GERM stock logo

About Amplify Treatments, Testing and Advancements ETF (NYSEARCA:GERM)

The ETFMG Treatments, Testing and Advancements ETF (GERM) is an exchange-traded fund that mostly invests in health care equity. The fund tracks a tier-weighted, narrow index of US-listed, global biotech companies that are engaged in the testing and treatments of infectious diseases. GERM was launched on Jun 17, 2020 and is managed by ETF Managers Group.

GERM Stock Price History

GERM ETF News Headlines

ETFMG Treatments Testing and Advancements ETF
How to Get Rich From A Miracle Drug Touted by Elon Musk
When it comes to the $15.7 trillion build out of A.I., we haven't even gotten started, folks. And that spells opportunity in 2024. Last year, a group of stocks dubbed "The Magnificent Seven" soared as investors piled into these A.I. leaders, sending shares of the group an average of 111%. Compare that to the S&P 500's 24% gain... it's no contest.
GERM ETFMG Treatments, Testing and Advancements ETF
Lactose Intolerance Treatment Market Growth by 2031
How to Get Rich From A Miracle Drug Touted by Elon Musk
When it comes to the $15.7 trillion build out of A.I., we haven't even gotten started, folks. And that spells opportunity in 2024. Last year, a group of stocks dubbed "The Magnificent Seven" soared as investors piled into these A.I. leaders, sending shares of the group an average of 111%. Compare that to the S&P 500's 24% gain... it's no contest.
See More Headlines
Receive GERM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amplify Treatments, Testing and Advancements ETF and its competitors with MarketBeat's FREE daily newsletter.

Fund Details

Issuer
Amplify
Fund Name
Amplify Treatments, Testing and Advancements ETF
Tax Classification
Regulated Investment Company
Current Symbol
NYSEARCA:GERM
Inception Date
6/17/2020
Fund Manager
Charles Ragauss, Qiao Duan
Web
N/A
Phone
N/A

Fund Focus

Asset Class
Equity
Benchmark
Prime Treatments, Testing and Advancements Index
Category
Strategy
Focus
Theme
Development Level
Blended Development
Region
Global
Number of Holdings
57

Fund Statistics

Assets Under Management
$10.69 million
Average Daily Volume
$0.00
Discount/Premium
-0.11%

Administrator, Advisor and Custodian

Administrator
U.S. Bancorp Fund Services, LLC
Advisor
Amplify Investments LLC
Custodian
U.S. Bank, N.A.
Distributor
Foreside Fund Services, LLC
Transfer Agent
U.S. Bancorp Fund Services, LLC
Trustee
N/A
Lead Market Maker
Virtu Financial

Options

Optionable
N/A
Short Interest
100 shs

Miscellaneous

Beta
0.84
Creation Unit
50,000
Creation Fee
$300.00
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Amplify Treatments, Testing and Advancements ETF Expenses

TypeGERMTheme ETFsEquity ETFsNYSEARCA ETFsAll ETFs
Management Fee0.68%0.57%0.54%0.50%0.51%
Other Expenses0.00%0.71%0.54%0.64%0.58%
Total Expense0.68%0.72%0.70%0.74%0.70%
Fee Waiver0.00%-0.76%-0.55%-0.68%-0.57%
Net Expense0.68%0.59%0.60%0.58%0.58%

Amplify Treatments, Testing and Advancements ETF (GERM) Holdings & Exposure

GERM Sector Exposure

GERM Industry Exposure


GERM ETF - Frequently Asked Questions

How have GERM shares performed in 2024?

Amplify Treatments, Testing and Advancements ETF's stock was trading at $19.56 on January 1st, 2024. Since then, GERM shares have decreased by 12.7% and is now trading at $17.0754.
View the best growth stocks for 2024 here
.

What does GERM invest in?

Amplify Treatments, Testing and Advancements ETF is a equity fund issued by Amplify. GERM focuses on theme investments and follows the Prime Treatments, Testing and Advancements Index. The fund's investments total to approximately $10.69 million assets under management.

What stocks does Amplify Treatments, Testing and Advancements ETF hold?
What is the management fee for Amplify Treatments, Testing and Advancements ETF?

Amplify Treatments, Testing and Advancements ETF's management fee is 0.68% and has no other recorded expenses or fee waivers. The net expense ratio for GERM is 0.68%.

What other stocks do shareholders of Amplify Treatments, Testing and Advancements ETF own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amplify Treatments, Testing and Advancements ETF investors own include Village Farms International (VFF), Charlotte's Web (CWBHF), 3 Sixty Risk Solutions (PTVYF), Inovio Pharmaceuticals (INO), Moderna (MRNA), PayPal (PYPL), AbbVie (ABBV), Auxly Cannabis Group (CBWTF).

How do I buy shares of Amplify Treatments, Testing and Advancements ETF?

Shares of GERM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSEARCA:GERM) was last updated on 4/13/2024 by MarketBeat.com Staff

From Our Partners